Harry Sokol

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3791009/publications.pdf

Version: 2024-02-01

256 papers	30,597 citations	7561 77 h-index	5249 165 g-index
275 all docs	275 docs citations	275 times ranked	29348 citing authors

#	Article	IF	Citations
1	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16731-16736.	3.3	3,581
2	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biology, 2012, 13, R79.	13.9	2,258
3	Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host and Microbe, 2018, 23, 716-724.	5.1	1,442
4	Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases, 2009, 15, 1183-1189.	0.9	1,052
5	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature Medicine, 2016, 22, 598-605.	15.2	1,001
6	Fungal microbiota dysbiosis in IBD. Gut, 2017, 66, 1039-1048.	6.1	939
7	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 223-237.	8.2	893
8	Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology, 2013, 16, 255-261.	2.3	829
9	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	6.1	793
10	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, 2013, 62, 531-539.	6.1	663
11	A microbial signature for Crohn's disease. Gut, 2017, 66, 813-822.	6.1	657
12	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	6.6	645
13	Identification of an anti-inflammatory protein fromFaecalibacterium prausnitzii, a commensal bacterium deficient in Crohnâ€™s disease. Gut, 2016, 65, 415-425.	6.1	585
14	Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut, 2021, 70, 1174-1182.	6.1	519
15	Specificities of the fecal microbiota in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 106-111.	0.9	373
16	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. Cell Metabolism, 2018, 28, 737-749.e4.	7.2	356
17	Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunology, 2018, 11, 1024-1038.	2.7	326
18	Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic. Frontiers in Microbiology, 2017, 8, 1226.	1.5	320

#	Article	IF	Citations
19	Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nature Communications, 2018, 9, 2802.	5.8	317
20	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	6.1	290
21	Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 1614-1622.	0.5	266
22	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohnâ€™s Disease Patients. Journal of Crohn's and Colitis, 2016, 10, 296-305.	0.6	252
23	The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 331-345.	8.2	226
24	Increase in fecal primary bile acids and dysbiosis in patients with diarrheaâ€predominant irritable bowel syndrome. Neurogastroenterology and Motility, 2012, 24, 513.	1.6	209
25	Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiology, 2015, 15, 67.	1.3	208
26	Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii. MBio, 2015, 6, .	1.8	206
27	The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. Inflammatory Bowel Diseases, 2014, 20, 417-430.	0.9	204
28	Fecal microbiota transplantation to maintain remission in Crohnâ€™s disease: a pilot randomized controlled study. Microbiome, 2020, 8, 12.	4.9	203
29	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68, 1504-1515.	6.1	202
30	Analysis of bacterial bowel communities of IBD patients: What has it revealed?. Inflammatory Bowel Diseases, 2008, 14, 858-867.	0.9	193
31	Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nature Medicine, 2018, 24, 1113-1120.	15.2	193
32	Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific Reports, 2016, 6, 18507.	1.6	174
33	Reporting guidelines for human microbiome research: the STORMS checklist. Nature Medicine, 2021, 27, 1885-1892.	15.2	170
34	Effectiveness and Safety of Vedolizumab Induction Therapy forÂPatients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	2.4	168
35	Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2014, 20, 1.	0.9	160
36	Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Frontiers in Immunology, 2017, 8, 1553.	2.2	156

#	Article	IF	Citations
37	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut, 2010, 59, 1363-1368.	6.1	155
38	The Gut Microbiota at the Service of Immunometabolism. Cell Metabolism, 2020, 32, 514-523.	7.2	152
39	Lactobacillus rhamnosusCNCM I-3690 and the commensal bacteriumFaecalibacterium prausnitziiA2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes, 2015, 6, 1-9.	4.3	143
40	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2402-2409.	0.9	143
41	Enterobacteriaceae are essential for the modulation of colitis severity by fungi. Microbiome, 2018, 6, 152.	4.9	143
42	Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes, 2018, 9, 131-142.	4.3	142
43	Postoperative Complications after Ileocecal Resection in Crohnâ€™s Disease: A Prospective Study From the REMIND Group. American Journal of Gastroenterology, 2017, 112, 337-345.	0.2	138
44	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut, 2020, 69, 92-102.	6.1	136
45	Tryptophan Metabolism as a Pharmacological Target. Trends in Pharmacological Sciences, 2021, 42, 60-73.	4.0	135
46	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Current Opinion in Gastroenterology, 2010, 26, 327-331.	1.0	133
47	Temperature Gradient Gel Electrophoresis of Fecal 16S rRNA Reveals Active Escherichia coli in the Microbiota of Patients with Ulcerative Colitis. Journal of Clinical Microbiology, 2006, 44, 3172-3177.	1.8	131
48	Card9 Mediates Intestinal Epithelial Cell Restitution, T-Helper 17 Responses, and Control of Bacterial Infection in Mice. Gastroenterology, 2013, 145, 591-601.e3.	0.6	131
49	Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). Journal of Crohn's and Colitis, 2014, 8, 31-44.	0.6	130
50	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
51	Ecology and metabolism of the beneficial intestinal commensal bacteriumFaecalibacterium prausnitzii. Gut Microbes, 2014, 5, 146-151.	4.3	128
52	Oneâ€year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2017, 46, 310-321.	1.9	128
53	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 2014, 63, 1416-1423.	6.1	122
54	Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. International Journal of Food Microbiology, 2010, 144, 35-41.	2.1	117

#	Article	IF	Citations
55	CD4CD8Î±Î± Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease. PLoS Biology, 2014, 12, e1001833.	2.6	117
56	Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal Î³Î´ TÂcells. Cell Reports, 2021, 36, 109332.	2.9	114
57	Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. Cell Reports, 2020, 32, 107915.	2.9	113
58	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	6.1	110
59	Factors affecting outcomes in Crohn's disease over 15â€...years. Gut, 2012, 61, 1140-1145.	6.1	108
60	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432.	3.7	108
61	Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. Cell Metabolism, 2015, 22, 460-471.	7.2	107
62	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 1330-1340.	1.6	103
63	Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. Gut, 2009, 58, 1218-1225.	6.1	101
64	Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. ISME Journal, 2016, 10, 460-477.	4.4	100
65	Phages infecting Faecalibacterium prausnitzii belong to novel viral genera that help to decipher intestinal viromes. Microbiome, 2018, 6, 65.	4.9	98
66	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, 2020, 12, .	5.8	98
67	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	0.9	96
68	Toll-like receptor 2 is critical for induction of Reg3Â expression and intestinal clearance of Yersinia pseudotuberculosis. Gut, 2009, 58, 771-776.	6.1	93
69	Gut Fungal Microbiota. Inflammatory Bowel Diseases, 2015, 21, 656-665.	0.9	93
70	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. Gut, 2021, 70, 1299-1308.	6.1	92
71	Impact of vedolizumab therapy on extraâ€intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>â€<scp>IBD</scp> cohort. Alimentary Pharmacology and Therapeutics, 2018, 47, 485-493.	1.9	91
72	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica, 2019, 104, 1682-1688.	1.7	91

#	Article	IF	Citations
73	Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes, 2020, 12, 1826748.	4.3	90
74	Microbiota inÂneuroinflammationÂandÂsynaptic dysfunction: a focus on Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 19.	4.4	89
75	Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflammatory Bowel Diseases, 2010, 16, 1247-1253.	0.9	88
76	Crohn's disease of the vulva. Journal of Crohn's and Colitis, 2014, 8, 563-570.	0.6	87
77	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World Journal of Gastroenterology, 2008, 14, 3497.	1.4	87
78	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. Gut Microbes, 2018, 9, 55-60.	4.3	85
79	Gut Microbiota-Stimulated Innate Lymphoid Cells Support Î²-Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. Cell Metabolism, 2018, 28, 557-572.e6.	7.2	84
80	Bacterial protein signals are associated with Crohnâ€™s disease. Gut, 2014, 63, 1566-1577.	6.1	80
81	Dendritic cellâ€“derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science, 2020, 368, 186-189.	6.0	80
82	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterology Journal, 2020, 8, 303-313.	1.6	79
83	Effects of light smoking consumption on the clinical course of CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 734-741.	0.9	76
84	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	5.8	76
85	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohnâ€™s disease. Gut, 2020, 69, 462-472.	6.1	76
86	Impact of Probiotics on Risk Factors for Cardiovascular Diseases. A Review. Critical Reviews in Food Science and Nutrition, 2014, 54, 175-189.	5.4	75
87	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes, 2021, 13, 1-19.	4.3	75
88	Clinical, serological and genetic predictors of inflammatory bowel disease course. World Journal of Gastroenterology, 2012, 18, 3806.	1.4	75
89	Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 503-513.	8.2	74
90	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Alimentary Pharmacology and Therapeutics, 2009, 29, 1106-1113.	1.9	72

#	Article	IF	Citations
91	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Scientific Reports, 2016, 6, 19399.	1.6	72
92	Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Frontiers in Immunology, 2019, 10, 143.	2.2	72
93	New Insights into the Diversity of the Genus Faecalibacterium. Frontiers in Microbiology, 2017, 8, 1790.	1.5	71
94	Male gender, active smoking and previous intestinal resection are risk factors for postâ€operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 924-932.	1.9	71
95	Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis. American Journal of Gastroenterology, 2010, 105, 2405-2411.	0.2	69
96	Anti-inflammatory properties of dairy lactobacilli. Inflammatory Bowel Diseases, 2012, 18, 657-666.	0.9	68
97	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut, 2009, 58, 1427-1436.	6.1	66
98	Gastrointestinal manifestations in mastocytosis: AÂstudy of 83 patients. Journal of Allergy and Clinical Immunology, 2013, 132, 866-873.e3.	1.5	66
99	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genetics, 2018, 14, e1007329.	1.5	66
100	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterology Journal, 2021, 9, 229-247.	1.6	66
101	Effects in the use of a genetically engineered strain ofLactococcus lactisdelivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Human Vaccines and Immunotherapeutics, 2014, 10, 1611-1621.	1.4	65
102	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunology, 2016, 9, 1360-1365.	2.7	64
103	Postbiotics â€" when simplification fails to clarify. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 825-826.	8.2	63
104	Long-term Outcome of Patients With Crohn's Disease Who Respond to Azathioprine. Clinical Gastroenterology and Hepatology, 2013, 11, 389-394.	2.4	60
105	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 712-720.	1.9	59
106	Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study. Digestive and Liver Disease, 2017, 49, 643-646.	0.4	57
107	Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. Clinical Infectious Diseases, 2017, 64, 767-775.	2.9	57
108	Identification of novel anti-inflammatory probiotic strains isolated from pulque. Applied Microbiology and Biotechnology, 2016, 100, 385-396.	1.7	54

#	Article	IF	Citations
109	The microbiota: an underestimated actor in radiation-induced lesions?. Gut, 2018, 67, 1-2.	6.1	54
110	Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Digestive and Liver Disease, 2016, 48, 242-247.	0.4	53
111	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 59-67.	2.4	52
112	Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. Frontiers in Microbiology, 2016, 7, 608.	1.5	50
113	Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. Microbiome, 2019, 7, 111.	4.9	50
114	Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2013, 19, 2084-2090.	0.9	48
115	The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. ISME Journal, 2020, 14, 771-787.	4.4	48
116	Changes in the LÃ©mann Index Values During the First Years of Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1633-1640.e3.	2.4	47
117	Using murine colitis models to analyze probioticsâ€“host interactions. FEMS Microbiology Reviews, 2017, 41, S49-S70.	3.9	47
118	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes, 2022, 14, 2018900.	4.3	47
119	p40phox Expression Regulates Neutrophil Recruitment and Function during the Resolution Phase of Intestinal Inflammation. Journal of Immunology, 2012, 189, 3631-3640.	0.4	46
120	Complications and surgery in the inflammatory bowel diseases biological era. Current Opinion in Gastroenterology, 2014, 30, 378-384.	1.0	46
121	Probiotics and Antibiotics in IBD. Digestive Diseases, 2014, 32, 10-17.	0.8	43
122	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. PLoS ONE, 2018, 13, e0202587.	1.1	43
123	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	3.0	43
124	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 44, 1102-1113.	1.9	42
125	Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8Î±+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. Gastroenterology, 2018, 155, 1205-1217.	0.6	42
126	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohnâ€™s Disease. Gastroenterology, 2020, 159, 2193-2202.e5.	0.6	41

#	Article	IF	Citations
127	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. Gut, 2007, 56, 152-154.	6.1	40
128	Current smoking differentially affects blood mononuclear cells from patients with crohnÊ¼s disease and ulcerative colitis: Relevance to its adverse role in the disease. Inflammatory Bowel Diseases, 2012, 18, 1101-1111.	0.9	40
129	Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. Digestive and Liver Disease, 2014, 46, 1086-1092.	0.4	40
130	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. Gut, 2018, 67, 1836-1844.	6.1	38
131	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. Molecular Nutrition and Food Research, 2008, 52, 906-912.	1.5	35
132	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. PLoS Genetics, 2019, 15, e1008018.	1.5	35
133	T cell clonal expansions in ileal Crohnâ€™s disease are associated with smoking behaviour and postoperative recurrence. Gut, 2019, 68, 1961-1970.	6.1	35
134	Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. Trends in Pharmacological Sciences, 2020, 41, 900-908.	4.0	35
135	Factors Associated with Durable Response to Infliximab in CrohnÊ¼s Disease 5 Years and Beyond. Inflammatory Bowel Diseases, 2015, 21, 60-70.	0.9	34
136	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. Talanta, 2019, 195, 593-598.	2.9	33
137	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. Cancer Immunology Research, 2020, 8, 1407-1425.	1.6	33
138	Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation. Frontiers in Immunology, 2020, 11, 144.	2.2	33
139	Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. Genome Medicine, 2020, 12, 58.	3.6	33
140	The presence of the anti-inflammatory protein MAM, fromFaecalibacterium prausnitzii, in the intestinal ecosystem. Gut, 2016, 65, 882.1-882.	6.1	32
141	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 141-149.e2.	2.4	32
142	Beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 193-194.	8.2	30
143	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. Frontiers in Microbiology, 2018, 9, 565.	1.5	30
144	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 553-564.	1.9	30

#	Article	IF	Citations
145	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
146	Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation. Mucosal Immunology, 2018, 11, 1181-1190.	2.7	29
147	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. PLoS ONE, 2018, 13, e0201991.	1.1	29
148	Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 819-824.	0.6	28
149	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. Digestive Diseases, 2015, 33, 105-112.	0.8	28
150	Dietâ€Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatology Communications, 2018, 2, 1533-1549.	2.0	28
151	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	1.5	28
152	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: AÂretrospective case series. Journal of Allergy and Clinical Immunology, 2013, 132, 997-1000.e4.	1.5	26
153	A Scoring System to Determine Patientsâ€™ Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1602-1610.e1.	2.4	26
154	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Alimentary Pharmacology and Therapeutics, 2017, 46, 1077-1084.	1.9	23
155	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2020, 18, 150-157.e1.	2.4	23
156	Human CD4+CD8Î±+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight, 2022, 7, .	2.3	23
157	Tryptophan metabolites get the gut moving. Cell Host and Microbe, 2021, 29, 145-147.	5.1	22
158	Blockage of bacterial FimH prevents mucosal inflammation associated with Crohnâ€™s disease. Microbiome, 2021, 9, 176.	4.9	22
159	Circulating bile acids concentration is predictive of coronary artery disease in human. Scientific Reports, 2021, 11, 22661.	1.6	22
160	Role of adherent and invasiveEscherichia coliin Crohnâ€™s disease: lessons from the postoperative recurrence model. Gut, 2023, 72, 39-48.	6.1	22
161	Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye. Digestive Diseases, 2009, 27, 375-381.	0.8	21
162	Epsteinâ€“Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1449-1451.	0.9	21

#	Article	IF	Citations
163	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology, 2020, 18, 620-627.e1.	2.4	21
164	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094690.	1.4	21
165	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. Gut Microbes, 2022, 14, .	4.3	20
166	Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoside. Nephrology Dialysis Transplantation, 2004, 19, 1921-1922.	0.4	19
167	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohnâ€™s Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS ONE, 2016, 11, e0157191.	1.1	19
168	Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen. International Journal of Obesity, 2019, 43, 428-431.	1.6	19
169	Butyrate, a new microbiota-dependent player in CD8+ TÂcells immunity and cancer therapy?. Cell Reports Medicine, 2021, 2, 100328.	3.3	19
170	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms. Gut Microbes, 2022, 14, 2022997.	4.3	19
171	Specific changes in faecal microbiota are associated with familial Mediterranean fever. Annals of the Rheumatic Diseases, 2019, 78, 1398-1404.	0.5	18
172	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. World Journal of Gastroenterology, 2010, 16, 583.	1.4	18
173	Crosstalk between the hepatologist and the cardiologist: A future place for the lithocholic acid as a coronary atheroma risk factor?. Hepatology, 2012, 56, 2426-2426.	3.6	17
174	Caspase recruitment domain 9, microbiota, and tryptophan metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 243-247.	1.3	17
175	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	0.8	17
176	Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 349-355.	0.6	16
177	Oral delivery of pancreatitisâ€associated protein by Lactococcus lactis displays protective effects in dinitroâ€benzenesulfonicâ€acidâ€induced colitis model and is able to modulate the composition of the microbiota. Environmental Microbiology, 2019, 21, 4020-4031.	1.8	15
178	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterology Journal, 2019, 7, 1408-1410.	1.6	15
179	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. Journal of Clinical Immunology, 2021, 41, 185-193.	2.0	15
180	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2022, 16, 1269-1280.	0.6	15

#	Article	IF	Citations
181	Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. Inflammatory Bowel Diseases, 2010, 16, 356-357.	0.9	14
182	Microbiota in digestive cancers: our new partner?. Carcinogenesis, 2017, 38, 1157-1166.	1.3	14
183	The regenerating family member 3 Î² instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. Gut, 2019, 68, 1190-1199.	6.1	14
184	Sera from patients with Crohnâ€™s disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. Innate Immunity, 2010, 16, 381-390.	1.1	13
185	Current Smoking, Not Duration of Remission, Delays CrohnÊ¼s Disease Relapse Following Azathioprine Withdrawal. Inflammatory Bowel Diseases, 2010, 16, 362-363.	0.9	12
186	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 896-903.	0.6	12
187	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. Journal of Crohn's and Colitis, 2010, 4, 669-670.	0.6	11
188	Differences in epidemiological features between ulcerative colitis and Crohnâ€™s disease: The early life-programmed versus late dysbiosis hypothesis. Medical Hypotheses, 2018, 115, 19-21.	0.8	11
189	Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. Frontiers in Microbiology, 2018, 9, 2849.	1.5	11
190	Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkersâ€"Example of Crohnâ€™s Disease and Ulcerative Colitis Flare-Ups. Cells, 2022, 11, 1340.	1.8	11
191	Thalidomide as a Treatment for Refractory CGD Colitis. American Journal of Gastroenterology, 2009, 104, 1069-1069.	0.2	10
192	Risk of serious infection in healthcare workers with inflammatory bowel disease: a caseâ€€control study of the Groupe d'Etude ThÃ©rapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 2018, 48, 713-722.	1.9	10
193	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRIâ€¯+â€¯Durvalumab Â± Tremelimumab in second-line of patients with advanced gastric cancer. Digestive and Liver Disease, 2021, 53, 420-426.	0.4	10
194	Osteoarthritis and gut microbiome. Joint Bone Spine, 2021, 88, 105203.	0.8	10
195	Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. PLoS ONE, 2017, 12, e0184624.	1.1	10
196	Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. Journal of Crohn's and Colitis, 2016, 10, 375-376.	0.6	9
197	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. Mucosal Immunology, 2021, 14, 1127-1132.	2.7	9
198	Pure Ileal CrohnÊ¼s Disease Without Colonic Involvement After a Long Ileo-colonic Anastomosis (Lester) Tj ETQq0 0 0 rgBT /Overlock 1 in a Subset of Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2007, 13, 243-244.	0.9	8

#	Article	IF	Citations
199	Fecal Microbiota Transplantation: Do We Need Harmonization?. Clinical Infectious Diseases, 2017, 64, 1292-1292.	2.9	8
200	A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. Lancet Infectious Diseases, The, 2019, 19, 1161-1162.	4.6	8
201	Antibiotics: a trigger for inflammatory bowel disease?. The Lancet Gastroenterology and Hepatology, 2020, 5, 956-957.	3.7	8
202	Immune-mediated inflammatory diseases and nutrition: results from an online survey on patientsâ€™ practices and perceptions. BMC Nutrition, 2021, 7, 38.	0.6	8
203	Alteration of the gut microbiotaâ€™s composition and metabolic output correlates with COVID-19-like severity in obese NASH hamsters. Gut Microbes, 2022, 14, .	4.3	8
204	Unilateral carotid granulomatous arteritis and Crohn's disease. Revue Neurologique, 2010, 166, 542-546.	0.6	7
205	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: AÂstudy of a national retrospective cohort of 1375 patients over 10 years. Journal of Allergy and Clinical Immunology, 2022, 149, 2116-2125.	1.5	7
206	Deletion of both Dectin-1 and Dectin-2 affects the bacterial but not fungal gut microbiota and susceptibility to colitis in mice. Microbiome, 2022, 10, .	4.9	7
207	Renal Cortical Necrosis Related to Paraneoplastic Antiphospholipid Syndrome. American Journal of Kidney Diseases, 2006, 47, 1072-1074.	2.1	6
208	An Image-Based Genetic Assay Identifies Genes in T1D Susceptibility Loci Controlling Cellular Antiviral Immunity in Mouse. PLoS ONE, 2014, 9, e108777.	1.1	6
209	Inflammatory bowel disease after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 1365-1366.	1.3	6
210	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. Frontiers in Immunology, 2018, 9, 1039.	2.2	6
211	Fecal Microbiota Transplantation for Ulcerative Colitis. JAMA - Journal of the American Medical Association, 2019, 321, 2240.	3.8	6
212	Beneficial Effects of Exclusive Enteral Nutrition in CrohnÊ¼s Disease Are not Mediated by Faecalibacterium prausnitzii. Inflammatory Bowel Diseases, 2014, 20, E18.	0.9	5
213	Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. Clinical and Translational Medicine, 2020, 10, e163.	1.7	5
214	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	3.7	5
215	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Digestive and Liver Disease, 2021, 53, 1254-1259.	0.4	5
216	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 416-420.	2.7	4

#	Article	IF	Citations
217	Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs. Drug Discovery Today, 2020, 25, 1575-1579.	3.2	4
218	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials, 2020, 21, 455.	0.7	4
219	Excess Intestinal Lymphoproliferative Disorders in IBD. Gastroenterology, 2011, 140, S-42.	0.6	3
220	Gut microbiota in PSCÂ: From association to possible causality. Commentary to â€œGut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitisâ€•by Nakamoto et al., Nature Microbiology, January 2019. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 123-125.	0.7	3
221	Evolution of FMT â€“ From early clinical to standardized treatments. Biologicals, 2022, , .	0.5	3
222	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. , 2022, 1, 393-402.		3
223	Impact of the Ileal Microbiota on Surgical Site Infections in Crohnâ€™s Disease: A Nationwide Prospective Cohort. Journal of Crohn's and Colitis, 2022, , .	0.6	3
224	Single Immunoglobulin Infusion Can Reverse Hemodynamic Failure Associated With Severe Clostridium difficile Colitis. American Journal of Gastroenterology, 2009, 104, 2649-2650.	0.2	2
225	Body mass index and disease activity at treatment initiation. Inflammatory Bowel Diseases, 2010, 16, 714-715.	0.9	2
226	Impact of Aphthous Colitis at Diagnosis on Crohnâ€™s Disease Outcomes. Journal of Crohn's and Colitis, 2020, 14, 342-350.	0.6	2
227	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases. Neurogastroenterology and Motility, 2022, , e14320.	1.6	2
228	Gut Microbiota Reprogramming f Tryptophan Metabolism During Pregnancy Shapes Host Insulin Resistance. Gastroenterology, 2022, , .	0.6	2
229	Dysbiosis in Inflammatory Bowel Disease: A Link With Antimicrobial Peptides Secretion?. Gastroenterology, 2011, 140, S-328.	0.6	1
230	Crohn's Disease Associated Dysbiosis as a Predictive Factor of Clinical Relapse: A Microbiological Substudy of the GETAID-STORI Cohort. Gastroenterology, 2011, 140, S-48.	0.6	1
231	Colorectal neoplasia in <scp>PSC</scp>â€“<scp>IBD</scp> patients: are times changing?. Liver International, 2012, 32, 175-176.	1.9	1
232	Mature CD8 + Tâ€cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. Clinical Case Reports (discontinued), 2016, 4, 1088-1090.	0.2	1
233	The Presence of Adherent-Invasive Escherichia Coli (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease. Gastroenterology, 2017, 152, S9.	0.6	1
234	PS-126-Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e78.	1.8	1

#	Article	IF	Citations
235	Gut microbiome alterations in antiâ€NMDA receptor encephalitis: caveats for result interpretation. Annals of Clinical and Translational Neurology, 2020, 7, 153-154.	1.7	1
236	Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. United European Gastroenterology Journal, 2020, 8, 1145-1146.	1.6	1
237	Increased risk of permanent stoma in Crohnâ€™s disease associated with hidradenitis suppurativa: a caseâ€control study. Alimentary Pharmacology and Therapeutics, 2020, 52, 303-310.	1.9	1
238	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. , 0, .		1
239	Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Patients With Inflammatory Bowel Disease: Presidential Poster. American Journal of Gastroenterology, 2014, 109, S487.	0.2	1
240	Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea. BMC Microbiology, 2022, 22, 54.	1.3	1
241	SER-109 for Recurrent Clostridioides difficile Infection. New England Journal of Medicine, 2022, 386, 1956-1958.	13.9	1
242	Air mass pushing the liver. Digestive and Liver Disease, 2011, 43, 1025.	0.4	0
243	Predictors of a 15-Year Non Severe Course in Crohn's Disease. Gastroenterology, 2011, 140, S-777.	0.6	0
244	Letter: not the end of the role of antiâ€viral therapy in ulcerative colitis with cytomegalovirus reactivation â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1247-1248.	1.9	0
245	P1268 IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE IN CFTR KNOCKOUT MICE. Journal of Hepatology, 2014, 60, S512.	1.8	0
246	1120 Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S225.	0.6	0
247	Mo1852 Impact of Fertility Treatment on Inflammatory Bowel Disease Outcomes. Gastroenterology, 2016, 150, S795.	0.6	0
248	Editorial: mongersen in Crohn's disease â€“ a new contribution to the beginning of a longâ€awaited therapeutic revolution?. Alimentary Pharmacology and Therapeutics, 2016, 43, 838-839.	1.9	0
249	Inflammatory Bowel Diseases: How to Identify High-Risk Patients. , 2017, , 653-660.		0
250	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. United European Gastroenterology Journal, 2020, 8, 353-354.	1.6	0
251	How to Identify High-Risk Patients in Inflammatory Bowel Disease?. , 2012, , 713-725.		0
252	Abstract 585: Card9 Deficiency Accelerates Experimental Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0

#	Article	IF	Citations
253	The Gut Microbiome in Inflammatory Bowel Disease. , 2019, , 347-377.		0
254	Impact of Gut Mycobiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 194-194.	0.6	0
255	On the Determinants of IDO Activity in Patients With Familial Mediterranean Fever. Modern Rheumatology, 2022, , .	0.9	0
256	Specific gut microbiota taxa as a key source of variability in colitis model. Nature Reviews Gastroenterology and Hepatology, 0, , .	8.2	0